# Gebert Rüf Stiftung

> Gebert Rüf Stiftung is a VC fund in Basel backing Manufacturing and Medical. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Basel, Switzerland
- Total investments: 15
- Last investment: May 2026
- Lead investor: 47%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/grstiftung/
- X (Twitter): https://twitter.com/grstiftung_ch
- Website: http://grstiftung.ch

Gebert Rüf Stiftung is a VC fund in Basel focused on Manufacturing and Medical. Gebert Rüf Foundation is the largest Science Foundation of Switzerland with headquarters in Basel.

## Contacts

5 contacts available for Gebert Rüf Stiftung. Shizune tracks 1 team members at Gebert Rüf Stiftung. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/gebert-rüf-stiftung?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Grant | $79k–$364k |
| Pre-Seed | $300k–$4.5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 5 | 33% |
| Medical | 3 | 20% |
| Chemical | 2 | 13% |
| Biotechnology | 2 | 13% |
| Medical Device | 2 | 13% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 11 | 73% |
| Pre-Seed | 4 | 27% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Pascale Vonmont | Deputy Managing Director | 0 | https://shizune.co/investors/profile/pascale-vonmont |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BLEEDnFIRE Therapeutics | BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments |  | Grant | May 27, 2026 |  |
| EZRA Systems | EZRA Systems develops practical solutions for private mobile networks. EZRA Systems enables private mobile networks for temporary and demanding deployments. | $127.8K | Grant | May 05, 2026 |  |
| Symactiv | Symactiv produces and sells fertilizer and agricultural soils. | $128.3K | Grant | Mar 04, 2026 |  |
| Liquid | Liquid is a finance app that connects all bank accounts in one place. The app tracks income and expenses automatically and allows users to categorize transactions using drag and drop. It provides an analysis of spending and shows the current financial situation. Users can set savings targets and monitor their progress toward goals. The wishlistfeature lets users save items they plan to buy in the future. Liquid also generates financial forecasts to show expected income and expenses for the month. The app collects all financial data in one account and gives insights for managing money. | $128.3K | Grant | Mar 04, 2026 |  |
| OrthoSens | OrthoSens develops battery-free sensors that turn standard orthopedic implants into smart, data-driven devices. Unlike existing smart implant solutions that require an implanted battery making them too large and too risky to scale beyond large joints, OrthoSens moves all electronics outside the body. A paper-thin sensor integrates directly intoexisting implants with no battery, no surgical workflow change and zero explant risk. An external wearable powers the sensor wirelessly and collects real-time data on load, micromotion and bone fusion. The result is a footprint 250x smaller than battery-powered competitors, opening up additional spine, foot & ankle markets that existing solutions cannot address. The clinical need is clear: approximately 20% of post-surgical patients drive around 68% of total post-operative costs through missed complications, continuous implant monitoring exists to catch them earlier. Starting January 2026, 745 US hospitals enrolled in CMS's mandatory TEAM bundle are now accountable for 30-day episode costs, creating direct institutional demand for this data.OrthoSens generates revenue through three streams: sensor sales to orthopedic implant manufacturers (unlocking +$1,309 NTAP reimbursement per unit), a SaaS subscription capturing 40% of Medicare's $104/month RPM reimbursement per patient and post-market data analytics. The company has validated its technology across 3 functional prototypes, filed 2 core patents with favorable Freedom to Operate and secured $1.3M+ in non-dilutive funding. It is raising a $2.3M seed round to complete ISO-13485 certification, conduct the FDA pre-clinical study and file a 510(k) submission. The team is led by Gwenael Hannema (3x medtech founder), Dr. Oleg Kotsur (Head of R&D), and key employees, supported by experienced board members with leadership backgrounds at Novartis, Medtronic and J&J MedTech. | $188.6K | Grant | Nov 15, 2025 |  |
| Forgis | Forgis is leading the next industrial revolution by introducing industrial intelligence into factories, which boosts the competitiveness of Western manufacturing. | $4.5M | Pre-Seed | Nov 13, 2025 |  |
| Azure Cell Therapies | Azure Cell Therapies is a biotech company developing next-gen CGTs for neurodegenerative diseases | $189K | Grant | Jul 22, 2025 |  |
| SendMeBag | SendMeBag is to provide reusable shipping bags with a protective mechanism to reduce packaging waste and CO2 emissions for e-commerce. | $79.3K | Grant | Mar 24, 2025 |  |
| Pace Locator | Pace Locator's aim is to leverage the potential of common, noninvasive patient data to enable faster, more reliable diagnosis and, eventually, safer, more successful treatment. | $335.4K | Pre-Seed | Feb 26, 2025 |  |
| NXI Therapeutics | NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical andearly clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives. |  | Grant | Jun 18, 2024 |  |

10 of 15 investments shown.

## Co-investors
- [Venture Kick](https://shizune.co/investors/profile/venturekick) — VC Fund, 5 deals together
- [Innosuisse](https://shizune.co/investors/profile/innosuisse) — VC Fund, 4 deals together
- [Kickfund](https://shizune.co/investors/profile/kickfund) — VC Fund, 2 deals together
- [Alternative Bank Switzerland](https://shizune.co/investors/profile/alternative-bank-switzerland) — VC Fund, 1 deal together
- [Eurostars](https://shizune.co/investors/profile/eurostars) — VC Fund, 1 deal together
- [redalpine](https://shizune.co/investors/profile/redalpine-venture-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Manufacturing Investors in Switzerland](https://shizune.co/investors/manufacturing-investors-switzerland)
- [Manufacturing VC Funds in Switzerland](https://shizune.co/investors/manufacturing-vc-funds-switzerland)
- [Climate Investors in Switzerland](https://shizune.co/investors/climate-investors-switzerland)
- [Climate VC Funds in Switzerland](https://shizune.co/investors/climate-vc-funds-switzerland)
- [Real Estate Investors in Switzerland](https://shizune.co/investors/real-estate-investors-switzerland)
- [Real Estate VC Funds in Switzerland](https://shizune.co/investors/real-estate-vc-funds-switzerland)

## FAQ

### What does Gebert Rüf Stiftung invest in?

Gebert Rüf Stiftung invests primarily in Manufacturing, Medical and Chemical startups, most often at Grant and Pre-Seed stage. Most of the 15 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Gebert Rüf Stiftung's check size?

Gebert Rüf Stiftung typically joins rounds of $79k–$364k at Grant and $300k–$4.5M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gebert Rüf Stiftung participates in.

### How do I contact Gebert Rüf Stiftung?

Public channels for Gebert Rüf Stiftung include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Gebert Rüf Stiftung?

The team at Gebert Rüf Stiftung includes Pascale Vonmont (Deputy Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co